Imaging Technology

AUGUST 29, 2023

Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.

Pharmaceutical 97

Pharmaceutical Radiopharmaceuticals Clinic Medical 97

Imaging Technology

JULY 5, 2023

Nucleus will use NorthStar’s Ac-225 for their customers’ radioligand pharmaceutical programs. Ac-225 carries sufficient radiation to cause cell death in a localized area of targeted cells, while its half-life limits unwanted radioactivity in patients. NorthStar is positioned to be the first commercial-scale producer of n.c.a.

Medical 92

Medical Radiopharmaceuticals Pharmaceutical Radiation 92

Imaging Technology

APRIL 3, 2023

Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.

Medical 98

Medical Radiopharmaceuticals Pharmaceutical Radiation 98